{"name":"ASPIRE PHARMA LIMITED","company_number":"06828501","status":"Active","type":"Private Limited Company","incorporated":"2009-02-24","dissolved":null,"registered_office":"102 High Street, Godalming, Surrey, GU7 1DS","postcode":"GU7 1DS","sic_codes":[{"code":46460,"description":"Wholesale of pharmaceutical goods"}],"principal_activity":null,"previous_names":[],"warnings":[],"accounts":{"category":"Full","year_end":"31 December","last_made_up_to":"2025-12-31","next_due":"2027-09-30"},"employees":{"count":114,"accounts_date":"2025-12-31"},"financials":[{"financial_date":"2025-12-31","profit_loss":21824,"net_assets":87624,"cash":7034,"average_employees":114},{"financial_date":"2024-12-31","profit_loss":23092,"net_assets":65800,"cash":8507,"average_employees":100},{"financial_date":"2023-12-31","profit_loss":19533952,"net_assets":48507716,"cash":9678345,"average_employees":79},{"financial_date":"2022-12-31","net_assets":48216951,"cash":8838159},{"financial_date":"2021-12-31","turnover":62703489,"net_assets":46229764,"cash":9189523}],"officers":{"current":8,"resigned":8,"complete":true,"note":"Names and details of individual officers are on the People page (subscriber-only on this site) and free at Companies House."},"charges":{"total":0,"outstanding":0},"gazette_notices":[],"insolvency_outcome":null,"ai_summary":"Aspire Pharma has built a compelling niche pharmaceutical platform combining regulatory expertise, private equity backing, and disciplined acquisition execution—evidenced by net assets growing from £17.6m to £65.8m over six years and turnover exceeding £115m in 2024. The company's strategic trajectory is sound, with EU expansion and a normalizing regulatory environment providing meaningful growth optionality, though management must address the operating profit decline and ensure the organizational capacity exists to execute on multiple fronts simultaneously. The next 18-24 months will be pivotal: if Aspire can translate its pipeline and geographic expansion into sustained profitable growth while maintaining cost discipline, it will cement its position as the leading UK-based niche pharmaceutical platform.","website":"https://aspirepharma.com/","links":{"page":"https://www.companiesintheuk.co.uk/ltd/aspire-pharma","people":"https://www.companiesintheuk.co.uk/company/aspire-pharma/people","filing_history":"https://www.companiesintheuk.co.uk/company/aspire-pharma/filing-history","companies_house":"https://find-and-update.company-information.service.gov.uk/company/06828501","financials":"https://www.companiesintheuk.co.uk/company/aspire-pharma/financial","control":"https://www.companiesintheuk.co.uk/company/aspire-pharma/control","charges":"https://www.companiesintheuk.co.uk/company/aspire-pharma/charges","ai_analysis":"https://www.companiesintheuk.co.uk/company/aspire-pharma/analysis"},"source":"CompaniesInTheUK, from Companies House, The Gazette and other public registers (see /support/about). Cite as: CompaniesInTheUK, https://www.companiesintheuk.co.uk/ltd/aspire-pharma"}